ATPW
CPRX

Ashton Thomas Private Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Sell
37,458
-834
-2% -$24.6K 0.02% 517
2026
Q1 		$948K Buy
38,292
+23,611
+161% +$562K 0.02% 548
2025
Q4 		$343K Buy
14,681
+315
+2% +$7.02K 0.01% 776
2025
Q3 		$283K Sell
14,366
-1,645
-10% -$33.8K 0.01% 819
2025
Q2 		$347K Buy
16,011
+2,997
+23% +$70.7K 0.01% 648
2025
Q1 		$316K Buy
13,014
+899
+7% +$20.2K 0.01% 643
2024
Q4 		$253K Buy
12,115
+276
+2% +$5.93K 0.01% 681
2024
Q3 		$235K Buy
11,839
+84
+0.7% +$1.56K 0.01% 558
2024
Q2 		$182K Buy
11,755
+342
+3% +$5.32K 0.01% 586
2024
Q1 		$182K Buy
11,413
+1,014
+10% +$15.3K 0.01% 577
2023
Q4 		$175K Sell
10,399
-190
-2% -$2.6K 0.01% 562
2023
Q3 		$124K Buy
10,589
+190
+2% +$2.54K 0.01% 550
2023
Q2 		$140K Buy
+10,399
New +$150K 0.01% 558

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ashton Thomas Private Wealth's CPRX Position: Q2 2026 in Review

Ashton Thomas Private Wealth reduced its Catalyst Pharmaceutical (CPRX) stake by 2.2% in Q2 2026, selling an estimated $24.6K and leaving 37,458 shares worth $1.18M. The position accounts for 0.02% of the portfolio, ranked #517.

Ashton Thomas Private Wealth first reported a position in CPRX in Q2 2023 and has held it in 13 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Ashton Thomas Private Wealth held 37,458 shares of Catalyst Pharmaceutical worth $1.18M as of Q2 2026.
  • Ashton Thomas Private Wealth sold 834 Catalyst Pharmaceutical shares in Q2 2026, an estimated $24.6K.
  • Catalyst Pharmaceutical made up 0.02% of Ashton Thomas Private Wealth's portfolio in Q2 2026, its #517 holding.
  • Ashton Thomas Private Wealth first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.